Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial

BACKGROUND: Sublingually administered asenapine was approved in March 2015 by the United States Food and Drug Administration for patients aged 10–17 years with an acute manic or mixed episode associated with bipolar I disorder (BP-1). This is the first long-term safety and tolerability study of asen...

Descripción completa

Detalles Bibliográficos
Autores principales: Findling, Robert L., Landbloom, Ronald L., Mackle, Mary, Wu, Xiao, Snow-Adami, Linda, Chang, Kiki, Durgam, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018262/
https://www.ncbi.nlm.nih.gov/pubmed/27461426
http://dx.doi.org/10.1007/s40272-016-0184-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018262/
https://www.ncbi.nlm.nih.gov/pubmed/27461426
http://dx.doi.org/10.1007/s40272-016-0184-2

Ejemplares similares